AbbVie vs Johnson & Johnson ABBV vs JNJ
AbbVie and Johnson & Johnson on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Trailing P/E: AbbVie 80.6×, Johnson & Johnson 29.7×.
- Net margin: Johnson & Johnson 21.5%, AbbVie 9.8%.
- One-year price return: Johnson & Johnson +33.0%, AbbVie +25.8%.
- Price / sales: AbbVie 7.8×, Johnson & Johnson 6.3×.
Price return
2025-10-16 → 2026-10-16
ABBV+25.8%
JNJ+33.0%
Profile
latestSector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
Market value
$504.37B
$615.87B
Enterprise value
$568.62B
$644.49B
Employees
57,000
141,700
Revenue per employee (TTM)
$1.1M
$691K
Our models
nightlythe valuation on each stock's pagePrice vs model
at model vs model
36% undervalued vs model
Model range
$162–725
$231–839
Models in the headline
1
1
FCF growth priced in, at a 10% return
18.1%
18.6%
Every model, its assumptions and its range: ABBV valuation · JNJ valuation. The growth priced in, at any return: ABBV reverse DCF · JNJ reverse DCF.
Trading
close 2026-10-16Last close
$285.42
$255.56
52-week high
$285.42
$278.43
52-week low
$197.38
$186.00
Price vs 52-week high
0.0%
−8.2%
Price vs 52-week low
+44.6%
+37.4%
Average daily volume / shares
0.3%
0.3%
Beta
0.28
0.23
Returns
to 2026-10-161 month
+8.7%
−4.4%
3 months
+12.2%
+2.2%
6 months
+36.6%
+9.0%
Year to date
+24.9%
+23.5%
1 year
+25.8%
+33.0%
1 year, dividends added
+28.9%
+35.8%
2 years
+49.9%
+55.6%
Valuation
price × TTM to Jun 2026P/E (TTM)
80.6×
29.7×
P/E on consensus EPS (next FY)
20.5×
22.8×
Price / sales
7.8×
6.3×
EV / sales
8.8×
6.6×
EV / EBITDA
—
—
Price / book
—
7.2×
Price / free cash flow (FY)
28.3×
31.3×
Free-cash-flow yield (FY)
3.5%
3.2%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+10.6%
+7.5%
Revenue, 3-year CAGR
1.8%
−0.3%
Revenue, 5-year CAGR
6.0%
2.7%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+489.7%
+1.4%
EPS, 3-year CAGR
−29.1%
17.9%
Free cash flow, 3-year CAGR
−9.8%
4.7%
Diluted shares, 3-year change
−0.3%
−8.8%
Profitability
TTM to Jun 2026Gross margin (FY)†
70.2%
67.9%
Operating margin
26.2%
—
EBITDA margin
—
—
Net margin
9.8%
21.5%
Free-cash-flow margin (FY)
29.1%
20.9%
Return on equity
—
24.8%
Return on assets
4.7%
10.5%
Asset turnover
0.48
0.49
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
MRQ Jun 2026Cash
$6.57B
$20.42B
Total debt
$70.82B
$49.04B
Net debt
$64.25B
$28.61B
Debt / equity
—
0.6×
Net debt / EBITDA (TTM)
—
—
Interest coverage (FY)
6.9×
26.4×
Current ratio (FY)
0.67
1.03
Dividends
trailing 12 monthsDividend yield
2.4%
2.1%
Dividends per share
$6.92
$5.28
Payout ratio (of TTM EPS)
195.5%
61.3%
Dividend per share, 5-year CAGR
5.9%
5.0%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
8
15
Insider open-market buys (Form 4)
$0
$0
Insider sales (Form 4)
$8.2M
$67.8M
Analyst upgrades
2
0
Analyst downgrades
0
0
Statements
income TTM to Jun 2026 · cash flow FY2025Revenue
$64.39B
$97.93B
EBITDA
—
—
Operating income
$16.87B
—
Net income
$6.31B
$21.04B
EPS (diluted)
$3.54
$8.61
Operating cash flow
$19.03B
$24.53B
Capital expenditure
−$1.21B
−$4.83B
Free cash flow
$17.82B
$19.70B
Dividends paid
$11.66B
—
Statements from the companies' SEC filings; prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.